Subscribe

Avacta Group Plc (AVCT.L)

GBp69.00 +0.00 (+0.00%)
GB LSE Healthcare Biotechnology
Address Thorp Arch Estate LS23 7FA
Wetherby, GB
CEO Christina Marie Coughlin
Website avacta.com
IPO 2003-09-08
ISIN GB00BYYW9G87

Explore sections of this company profile

Also trades on London Stock Exchange · AVCT.L (GBp) Other OTC · AVCTF (USD)
Description

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp69.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.07
Float Shares
393.04M
Free Float %
89.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+4.64% -1.10% +6.76% +17.04% -2.95% +36.21% +107.89% -25.19% -67.21% -26.82% -78.93%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
69.00
DCF (Levered) 0.12 -99.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-5.41
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    +0.0% Q4'25: -99.5% (vs Q2'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    +40.0% ★ Q4'25: -14.3% (vs Q2'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -32,100.9% Q4'25: -19,742.1% (vs Q2'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -26,756.6% Q4'25: -30,075.4% (vs Q2'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -5,619.9% Q4'25: -12,745.7% (vs Q2'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +22.3% Q4'25: +62.2% (vs Q2'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.52× Q4'25: -0.22× (vs Q2'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.10) × ERP
WACC = 95% × Ke + 5% × Kd (47.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 69.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
3 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
Revenue
1.81M
est: 2.00M (-9.4%)
2.17M
est: 2.18M (-0.5%)
2.74M
est: 2.75M (-0.5%)
2.76M
est: 3.00M (-7.9%)
3.89M
est: 3.10M (+25.5%)
2.14M
est: 4.00M (-46.4%)
2.94M
est: 4.50M (-34.6%)
9.65M
est: 7.70M (+25.4%)
2.85M
est: 22.62M (-87.4%)
113.0K
est: 23.03M (-99.5%)
113.0K
est: 2.12M (-94.7%)
32.42M
32.42M – 32.42M
+1,428.4% YoY
28.71M
28.71M – 28.71M
-11.4% YoY
192.0K
192.0K – 192.0K
-99.3% YoY
EBITDA
-2.68M
est: -2.00M (-33.8%)
-4.32M
est: -2.18M (-98.6%)
-6.31M
est: -2.75M (-129.5%)
-8.36M
est: -3.00M (-178.5%)
-8.40M
est: -3.10M (-170.8%)
-16.40M
est: -13.88M (-18.2%)
-26.69M
est: -4.50M (-493.1%)
-34.78M
est: -10.63M (-227.1%)
-14.12M
est: -22.62M (+37.6%)
-17.62M
est: -23.03M (+23.5%)
-28.96M
est: -2.12M (-1,265.2%)
-32.42M
-32.42M – -32.42M
-1,428.4% YoY
-28.71M
-28.71M – -28.71M
+11.4% YoY
-192.0K
-192.0K – -192.0K
+99.3% YoY
EBIT
-3.16M
est: -2.00M (-58.0%)
-5.66M
est: -2.18M (-160.4%)
-7.98M
est: -2.75M (-190.2%)
-10.39M
est: -3.00M (-246.3%)
-11.18M
est: -3.10M (-260.7%)
-18.56M
est: -17.70M (-4.8%)
-29.19M
est: -14.92M (-95.7%)
-37.79M
est: -13.57M (-178.6%)
-15.41M
est: -22.62M (+31.9%)
-19.13M
est: -23.03M (+16.9%)
-30.24M
est: -2.12M (-1,325.5%)
-32.42M
-32.42M – -32.42M
-1,428.4% YoY
-28.71M
-28.71M – -28.71M
+11.4% YoY
-192.0K
-192.0K – -192.0K
+99.3% YoY
Net Income
-10.14M
est: -16.34M (+37.9%)
-4.65M
est: -17.37M (+73.2%)
-6.37M
est: -28.84M (+77.9%)
-8.83M
est: -35.86M (+75.4%)
-11.02M
est: -29.74M (+62.9%)
-18.89M
est: -15.33M (-23.2%)
-26.32M
est: -21.20M (-24.1%)
-36.94M
est: -42.08M (+12.2%)
-24.95M
est: -34.33M (+27.3%)
-52.84M
est: -32.90M (-60.6%)
-38.38M
est: -23.98M (-60.0%)
-21.51M
-27.11M – -15.91M
+10.3% YoY
-20.21M
-20.21M – -20.21M
+6.1% YoY
—
— – —
+100.0% YoY
SGA
3.96M
est: 47.75M (-91.7%)
4.19M
est: 51.93M (-91.9%)
6.15M
est: 65.65M (-90.6%)
6.55M
est: 71.62M (-90.8%)
7.25M
est: 74.01M (-90.2%)
6.99M
est: 95.49M (-92.7%)
13.07M
est: 107.43M (-87.8%)
13.52M
est: 183.83M (-92.6%)
10.44M
est: 1.01B (-99.0%)
12.05M
est: 1.03B (-98.8%)
12.16M
est: 94.90M (-87.2%)
1.45B
1.45B – 1.45B
+1,428.4% YoY
1.28B
1.28B – 1.28B
-11.4% YoY
8.59M
8.59M – 8.59M
-99.3% YoY
EPS
-0.20
est: -0.05 (-300.1%)
-0.07
est: -0.05 (-29.1%)
-0.09
est: -0.09 (-5.5%)
-0.13
est: -0.11 (-18.5%)
-0.09
est: -0.09 (-0.7%)
-0.08
est: -0.07 (-23.1%)
-0.11
est: -0.09 (-22.0%)
-0.14
est: -0.09 (-62.4%)
-0.09
est: -0.09 (-6.6%)
-0.16
est: -0.08 (-94.5%)
-0.10
est: -0.06 (-51.7%)
-0.06
-0.07 – -0.04
+9.3% YoY
-0.05
-0.05 – -0.05
+11.9% YoY
—
— – —
+100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-28 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-47.57M
OE per share TTM
-0.11
Owner's Yield
-13.79%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
158.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-2.0K
Shares Outstanding
437.41M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Christina Coughlin Chief Executive Officer & Executive Director 551.0K —
Brian Hahn Chief Financial Officer & Company Secretary 409.0K male
R. Craig Slater Chief Operating Officer of Diagnostics 69.0K male
Emma Wright Group In-House Counsel — female
Karen Harrison Chief Operating Officer — female
Michael Vinegrad Group Communications Director — male
Anne McGurk Joint Managing Director of Launch Diagnostics — female
Sebastien Goenen Chief Operating Officer of Coris BioConcept — male
David Liebowitz Chief Medical Officer — —
David Wilson Chief Commercial Officer of Diagnostics — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology